LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING AND ADMINISTERING SAME
CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.
1 . A pharmaceutical formulation comprising a buffer, a tonicity agent, and a CTP-modified polypeptide sequence of interest and one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said polypeptide sequence of interest, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said polypeptide sequence of interest
2 . The pharmaceutical formulation of claim 1 , wherein said buffer is 10 mM citrate.
3 . The pharmaceutical formulation of any one of claims 1 - 2 , wherein said tonicity agent is 147 mM sodium chloride.
4 . The pharmaceutical formulation of any one of claims 1 - 3 , wherein said formulation is a liquid formulation.
5 . The pharmaceutical formulation of any one of claims 1 - 4 , wherein said formulation is at a pH of about 6.2-6.4.
6 . The pharmaceutical formulation of any one claims 1 - 5 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18
7 . The pharmaceutical formulation of any one of claims 1 - 6 , wherein said at least one CTP is glycosylated.
8 . The pharmaceutical formulation of any one of claims 1 - 7 , wherein said at least one CTP is truncated.
9 . The pharmaceutical formulation of any one of claims 1 - 8 , wherein said polypeptide optionally consists of a signal peptide attached to the amino terminus of said one CTP.
10 . The pharmaceutical formulation of claim 9 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19 or 26.
11 . The pharmaceutical formulation of any one of claims 1 - 10 , wherein at least one CTP is optionally attached to said polypeptide sequence of interest via a linker.
12 . The pharmaceutical formulation of claim 11 , wherein the linker is a peptide bond.
13 . The pharmaceutical formulation of any one of claims 1 - 12 , wherein said polypeptide is administered once weekly or once bi-weekly.
14 . The formulation of any one of claims 1 - 13 , wherein said subject is a human adult or a human child.
15 . The formulation of any one of claims 1 - 15 , for a once a week administration to a subject in need thereof.
16 . The formulation of claim 15 , wherein said administration is intravenous or subcutaneous administration.
17 . A process for making the pharmaceutical formulation of claims 1 - 16 for a once a week administration to a subject in need thereof, the process comprising the steps of: a. modifying a polypeptide sequence of interest by attaching one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said peptide of interest, and two chorionic gonadotropin CTPs attached to the carboxy terminus of said polypeptide sequence of interest; b. mixing the modifiedpolypeptide sequence of interest in step a. with said buffer, and said tonicity agent at a pH of 6.2-6.4; and c. pre-filling a syringe with said formulation.
18 . A process for filling a syringe with said formulation of any one of claims 1 - 16 , comprising the steps of: a. formulating a once a week dosage form of said CTP-modified polypeptide sequence of interest having a pre-determined amount of CTP-modified polypeptide sequence of interest; and, b. filling the syringe with said formulation.
19 . A pharmaceutical composition for a once a week administration to a subject having a deficiency associated with a polypeptide sequence of interest comprising a CTP-modified polypeptide sequence of interest and one chorionic gonadotropin carboxy terminal peptide (CTP) attached to the amino terminus of said polypeptide sequence of interest and two chorionic gonadotropin CTPs attached to the carboxy terminus of said polypeptide sequence of interest.
20 . The pharmaceutical composition of claim 20 , wherein the sequence of at least one CTP consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18.
21 . The pharmaceutical composition of any one of claims 20 - 21 , wherein said at least one CTP is glycosylated.
22 . The pharmaceutical composition of any one of claims 20 - 22 , wherein said at least one CTP is truncated.
23 . The pharmaceutical composition of any one of claims 20 - 23 , wherein said polypeptide optionally consists of a signal peptide attached to the amino terminus of said one CTP.
24 . The pharmaceutical formulation of claim 9 , wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19 or 26.
25 . The pharmaceutical composition of any one of claims 20 - 24 , wherein at least one CTP is optionally attached to said polypeptide sequence of interest via a linker.
26 . The pharmaceutical composition of claim 26 , wherein the linker is a peptide bond.
27 . The pharmaceutical composition of any one of claims 20 - 27 , wherein said polypeptide is administered once weekly or once bi-weekly.
28 . The pharmaceutical composition of any one of claims 20 - 28 , wherein said subject is a human adult or a human child.
29 . A once weekly dosage form comprising the pharmaceutical formulation of any one of claims 1 - 16 or the pharmaceutical composition of any one of claims 19 - 28 .